# Relutrigine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/relutrigine

> The PDUFA target action date for relutrigine, sponsored by Praxis Precision Medicines, Inc. (PRAX), is December 27, 2026, for SCN2A and SCN8A developmental and epileptic encephalopathies. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: year only, half-year only, month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the relutrigine PDUFA date?

The PDUFA target action date for relutrigine, sponsored by Praxis Precision Medicines, Inc. (PRAX), is December 27, 2026, for SCN2A and SCN8A developmental and epileptic encephalopathies. Status: scheduled. Press release filed with the SEC (EX-99): "56 D E V E L O P M E N T A L & E P I L E P T I C E N C E P H A L O P A T H I E S Relutrigine First medicine designed for SCN2A and SCN8A DEEs Dec 27, 2026 PDUFA date" Last confirmed November 12, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/relutrigine)

Source: Press release filed with the SEC (EX-99), accession 0001689548-26-000091, https://www.sec.gov/Archives/edgar/data/1689548/000168954826000091/praxis_investorxdayx2026.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/relutrigine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | relutrigine |
| Codes | PRAX-562 |
| Sponsor | Praxis Precision Medicines, Inc. (PRAX) https://sec-api.dev/companies/prax/catalysts |
| Indications | broad dees, scn2a and scn8a developmental and epileptic encephalopathies, or dees, scn2a and scn8a dees remains, scn2a and scn8a developmental and epileptic encephalopathies, scn2a-dee and scn8a-dee |
| Modality |  |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### 2025: topline data readout

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2025-07-17, last confirmed 2025-07-17.
- SEC Form 8-K (accession 0001689548-25-000086): "As previously disclosed, Praxis Precision Medicines, Inc. (the "Company") anticipates reporting topline results from the RADIANT Phase 2 study by mid-year 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000086/prax-20250717.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half.
- First seen 2025-01-29, last confirmed 2025-05-02.
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000056): "oPraxis has completed discussions with the FDA on a trial for broad DEEs and will initiate the EMERALD registrational study in mid-2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000021): "•Praxis remains on track to initiate the EMERALD registrational study in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/a8-kexhibit991.htm

### May 2025: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-08-04, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001689548-25-000111): "For our relutrigine program (formerly known as PRAX-562), we announced positive topline results from the first cohort of our EMBOLD study in the third quarter of 2024, and disclosed updated data from the study's open-label extension through 11 months in May 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000111/prax-20250930.htm
- SEC Form 10-Q (accession 0001689548-25-000092): "For our relutrigine program (formerly known as PRAX-562), we announced positive topline results from the first cohort of our EMBOLD study in the third quarter of 2024, and disclosed updated data from the study's open-label extension through 11 months in May 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000092/prax-20250630.htm

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-11-05, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000110): "The interim analysis is planned to be conducted in the fourth quarter of 2025.Relutrigine is also being investigated in patients across all DEEs in the EMERALD trial." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm
- SEC Form 10-Q (accession 0001689548-25-000111): "Following a comprehensive Type B meeting with the FDA, we will be performing an interim analysis of the second cohort of the ongoing EMBOLD study in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000111/prax-20250930.htm

### early 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-01-29, last confirmed 2025-12-11.
- SEC Form 8-K (accession 0001689548-25-000116): "On December 11, 2025, the Company announced the completion of the planned discussion with the FDA, leading to the confirmation to file a New Drug Application for relutrigine in SCN2A and SCN8A DEEs in early 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000116/prax-20251209.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000021): "We are also thrilled to have received a third rare pediatric drug designation (RPDD) for relutrigine in Dravet Syndrome, and with strong interest in cohort 2 of the EMBOLD study, we expect to file the NDA in 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/a8-kexhibit991.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-01-29, last confirmed 2025-05-02.
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000056): "Relutrigine has Rare Pediatric Disease Designation in three indications: SCN1A epilepsy (Dravet syndrome), SCN2A and SCN8A DEEs oThe EMBOLD registrational cohort 2 continues to enroll strongly, with topline results expected no later than the first half of 2026, followed by potential NDA filing." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000021): "•EMBOLD is currently enrolling 80 patients with SCN2A and SCN8A DEEs in registrational cohort 2, with topline results anticipated in the first half of 2026, to be followed by an NDA filing later in 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/a8-kexhibit991.htm

### September 27, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: SCN2A and SCN8A developmental and epileptic encephalopathies, or DEEs.
- First seen 2026-04-06, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA target action date of September 27, 2026" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "•The FDA has accepted with priority review the relutrigine NDA for the treatment of SCN2A and SCN8A DEEs, with a PDUFA target action date of September 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm
- SEC Form 10-Q (accession 0001689548-26-000089): "For our relutrigine program within the Cerebrum™ platform, we submitted an NDA for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies, or DEEs, to the FDA based on the positive results from the registrational cohort of the EMBOLD study in SCN2A-DEE and SCN8A-DEE, and it was accepted for priority review with a target PDUFA action date of September 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm
- SEC Form 10-Q (accession 0001689548-26-000083): "For our relutrigine program within the Cerebrum™ platform, we submitted an NDA for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies, or DEEs, to the FDA based on the positive results from the registrational cohort of the EMBOLD study in SCN2A-DEE and SCN8A-DEE, and it was accepted for priority review with a target PDUFA action date of September 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm
- SEC Form 10-Q (accession 0001689548-26-000047): "We submitted an NDA for relutrigine for the treatment of SCN2A-DEE and SCN8A-DEE to the FDA, and it was accepted for priority review with a target PDUFA action date of September 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000047/prax-20260331.htm
- SEC Form 8-K (accession 0001689548-26-000031): "The FDA has set a target action date under the Prescription Drug User Fee Act of September 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/prax-20260406.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "NDA accepted, with September 27, 2026 PDUFA target action date with priority review" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxiscorporatedeckmay_2.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Indication: broad DEEs.
- First seen 2026-05-07, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000086): "Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies (DEEs) expected in the fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000082): "•Topline results are anticipated in the fourth quarter of 2026 and assuming successful initial NDA approval of relutrigine, the EMERALD study, if positive, would serve as the basis for a supplemental NDA submission in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "Recruiting completed for relutrigine EMERALD study in broad DEEs, with topline results expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm
- SEC Form 10-Q (accession 0001689548-26-000089): "The EMERALD study, which is evaluating relutrigine in patients with broad DEEs, has completed recruitment, with topline results anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm
- SEC Form 10-Q (accession 0001689548-26-000083): "The EMERALD study, which is evaluating relutrigine in patients with broad DEEs, has completed recruitment, with topline results anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm
- SEC Form 10-Q (accession 0001689548-26-000047): "The EMERALD study, which is evaluating relutrigine in patients with broad DEEs, has completed recruitment, with topline results anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000047/prax-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000082): "20 EMERALD Study Targets Phenotypic DEEs, Regardless of Etiology Topline readout expected Q4 2026 Key Inclusion Criteria" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxiscorporatedeckaugus.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "•Recruitment for the EMERALD study in broad DEEs is complete, with topline results expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "20 EMERALD Study Targets Phenotypic DEEs, Regardless of Etiology Topline readout expected Q4 2026 Key Inclusion Criteria" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxiscorporatedeckmay_2.htm

### December 27, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: SCN2A and SCN8A developmental and epileptic encephalopathies.
- First seen 2026-06-29, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000091): "56 D E V E L O P M E N T A L & E P I L E P T I C E N C E P H A L O P A T H I E S Relutrigine First medicine designed for SCN2A and SCN8A DEEs Dec 27, 2026 PDUFA date" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000091/praxis_investorxdayx2026.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000086): "FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000086): "•The NDA for relutrigine for the treatment of SCN2A and SCN8A DEEs remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000082): "Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000082): "•Following the submission of additional sensitivity analyses of existing clinical data, which the FDA deemed collectively to be a major amendment, the FDA extended the review period for relutrigine's NDA for the treatment of SCN2A and SCN8A DEEs and set a new PDUFA target action date of December 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm
- SEC Form 8-K (accession 0001689548-26-000069): "On June 29, 2026, Praxis Precision Medicines, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") notified the Company that it has extended by three months the review period for its New Drug Application ("NDA") for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies ("DEEs"), setting an updated PDUFA target action date from September 27, 2026 to December 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/prax-20260629.htm
- SEC Form 10-Q (accession 0001689548-26-000089): "In June 2026, the FDA notified us that it had extended by three months the review period for our NDA for relutrigine, setting an updated PDUFA action date of December 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm
- SEC Form 10-Q (accession 0001689548-26-000083): "In June 2026, the FDA notified us that it had extended by three months the review period for our NDA for relutrigine, setting an updated PDUFA action date of December 27, 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000082): "NDA accepted, granted priority review, December 27, 2026 PDUFA target action date" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxiscorporatedeckaugus.htm

Calendar months: [September 2026](https://sec-api.dev/fda-calendar/2026-09), [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/relutrigine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Relutrigine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/relutrigine

```bibtex
@misc{secapidev_pdufa_relutrigine_20261116,
  title        = {Relutrigine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/relutrigine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_relutrigine_20261116","title":"Relutrigine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/relutrigine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
